GUTS:NASDAQ, Fractyl Health, Inc.
GUTS stock overview
Fractyl Health, Inc. (GUTS:NASDAQ) closed at $1.38 on October 19, 2026,
down 10.97% on the day.
The stock trades 95.3% below its 52-week high of $29.34
and 0.7% above its 52-week low of $1.37.
Over the past year, it lost 0.7%.
Fractyl Health, Inc. is part of the Health Care sector.
Key figures
- Price
- $1.38
- Day change
- -10.97%
- Volume
- 1,128,827
- Average volume
- 378,271
- Market cap
- 18M+
- 52-week range
- $1.37 – $29.34
- 50-day average
- $6.89
- 200-day average
- $9.07
Price action over the past year
In 251 trading sessions since October 17, 2025, GUTS closed higher on 109 days (43%).
Its best day was May 13, 2026 (+29.16%) and its worst was January 29, 2026 (-68.03%).
The stock moved 10% or more in a single session 21 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
GUTS news
-
Oct 16, 2026:
Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans
-
Oct 16, 2026:
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
-
Sep 30, 2026:
Robbins LLP is Investigating Allegations that Fractyl Health, Inc. Misled Investors Regarding the Viability and Efficacy of its Revita DMR System
-
Sep 16, 2026:
GUTS Stockholders Have Rights - If you Lost Money Investing in Fractyl Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses
-
Sep 9, 2026:
Fractyl Health to Participate in Upcoming September Investor Conferences
-
Sep 3, 2026:
Did You Lose Money Investing in Fractyl Health, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against GUTS
-
Sep 1, 2026:
Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance
-
Sep 1, 2026:
Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day
About Fractyl Health, Inc.
Fractyl Health is a leading metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including T2D and obesity. Our Revita and Rejuva platform candidates are designed to target root causes of metabolic diseases and to transform metabolic disease treatment from chronic management to potentially preventing and reversing metabolic disease.
Similar stocks
Find more stocks like GUTS with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.